PharmaTimesOriginal article
Polpharma Biologics gains FDA and EMA review acceptances
RegulatoryPB016Positive
AI Analysis
Summary
Polpharma Biologics announced that the FDA and EMA have accepted its PB016 vedolizumab biosimilar application for regulatory review. This marks a regulatory milestone for the company's biosimilar development program.
Outcome Details
FDA and EMA review acceptances for vedolizumab biosimilar application
Importance:6/10
Sentiment:
0.60
biosimilarFDA approvalEMA approvalvedolizumabregulatory milestone
Read the original article
Published by PharmaTimes on August 3, 2026 11:03 AM